Memantine, an uncompetitive low affinity NMDA open-channel antagonist improves clinical rating scores in a multiple infarct embolic stroke model in rabbits

Brain Research

Volumn 1088, Issue 1, 2006, Pages 141-147

  Lapchak, Paul A ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Acute ischemic stroke; Behavior; Clinical; Embolism; Neuroprotection; Toxicity

Indexed keywords

AMPICILLIN; DRUG VEHICLE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN EMBOLISM; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG EFFECT; LETHAL DOSE; NONHUMAN; PRIORITY JOURNAL; RABBIT; SCORING SYSTEM; STROKE;

ANIMALS; BRAIN INFARCTION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; INTRACRANIAL EMBOLISM; MALE; MEMANTINE; RABBITS; TIME FACTORS;

ORYCTOLAGUS CUNICULUS;

EID: 33747390182     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2006.02.093     Document Type: Article

References (42)

1. Bresink I., Danysz W., Parsons C.G., Tiedtke P., and Mutschler E. Chronic treatment with the uncompetitive NMDA receptor antagonist memantine influences the polyamine and glycine binding sites of the NMDA receptor complex in aged rats. J. Neural Transm., Parkinson's Dis. Dement. Sect. 10 (1995) 11-26
2. Bresink I., Benke T.A., Collett V.J., Seal A.J., Parsons C.G., Henley J.M., and Collingridge G.L. Effects of memantine on recombinant rat NMDA receptors expressed in HEK 293 cells. Br. J. Pharmacol. 119 (1996) 195-204
3. Buchan A.M. Do NMDA antagonists protect against cerebral ischemia: are clinical trials warranted?. Cerebrovasc. Brain Metab. Rev. 2 (1990) 1-26
4. Chen H.S., and Lipton S.A. Mechanism of memantine block of NMDA-activated channels in rat retinal ganglion cells: uncompetitive antagonism. J. Physiol. 499 Pt 1 (1997) 27-46
5. Chen H.S., Wang Y.F., Rayudu P.V., Edgecomb P., Neill J.C., Segal M.M., Lipton S.A., and Jensen F.E. Neuroprotective concentrations of the N-methyl-d-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation. Neuroscience 86 (1998) 1121-1132
6. Collins R.C., Dobkin B.H., and Choi D.W. Selective vulnerability of the brain: new insights into the pathophysiology of stroke. Ann. Intern Med. 110 (1989) 992-1000
7. Culmsee C., Junker V., Kremers W., Thal S., Plesnila N., and Krieglstein J. Combination therapy in ischemic stroke: synergistic neuroprotective effects of memantine and clenbuterol. Stroke 35 (2004) 1197-1202
8. Dirnagl U., Iadecola C., and Moskowitz M.A. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 22 (1999) 391-397
9. Finucane T.E. Memantine for patients with Alzheimer disease. JAMA 291 (2004) 1695 (author reply 1695)
10. Fisher M. Recommendations for advancing development of acute stroke therapies: stroke therapy academic industry roundtable 3 (STAIR-III). Stroke 34 (2003) 1539-1546
11. Frankiewicz T., and Parsons C.G. Memantine restores long term potentiation impaired by tonic N-methyl-d-aspartate (NMDA) receptor activation following reduction of Mg2+ in hippocampal slices. Neuropharmacology 38 (1999) 1253-1259
12. Frankiewicz T., Potier B., Bashir Z.I., Collingridge G.L., and Parsons C.G. Effects of memantine and MK-801 on NMDA-induced currents in cultured neurones and on synaptic transmission and LTP in area CA1 of rat hippocampal slices. Br. J. Pharmacol. 117 (1996) 689-697
13. Garcia J.H., and Anderson M.L. Physiopathology of cerebral ischemia. Crit. Rev. Neurobiol. 4 (1989) 303-324
14. Globus M.Y., Busto R., Dietrich W.D., Martinez E., Valdes I., and Ginsberg M.D. Effect of ischemia on the in vivo release of striatal dopamine, glutamate, and gamma-aminobutyric acid studied by intracerebral microdialysis. J. Neurochem. 51 (1988) 1455-1464
15. Gorgulu A., Kins T., Cobanoglu S., Unal F., Izgi N.I., Yanik B., and Kucuk M. Reduction of edema and infarction by memantine and MK-801 after focal cerebral ischaemia and reperfusion in rat. Acta Neurochir. (Wien) 142 (2000) 1287-1292
16. Hirsch C.H. Memantine was better than placebo in Alzheimer disease already being treated with donepezil. ACP J. Club 141 (2004) 38
17. Kochhar A., Zivin J.A., Lyden P.D., and Mazzarella V. Glutamate antagonist therapy reduces neurologic deficits produced by focal central nervous system ischemia. Arch. Neurol. 45 (1988) 148-153
18. Kochhar A., Zivin J.A., and Mazzarella V. Pharmacologic studies of the neuroprotective actions of a glutamate antagonist in ischemia. J. Neurotrauma 8 (1991) 175-186
19. Kornhuber J., Bormann J., Retz W., Hubers M., and Riederer P. Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur. J. Pharmacol. 166 (1989) 589-590
20. Lapchak P.A. 3alpha-OL-5-beta-pregnan-20-one hemisuccinate, a steroidal low-affinity NMDA receptor antagonist improves clinical rating scores in a rabbit multiple infarct ischemia model: synergism with tissue plasminogen activator. Exp. Neurol. 197 (2006) 531-537
21. Lapchak P.A., and Zivin J.A. Ebselen, a seleno-organic antioxidant, is neuroprotective after embolic strokes in rabbits: synergism with low-dose tissue plasminogen activator. Stroke 34 (2003) 2013-2018
22. Lapchak P.A., Araujo D.M., Song D., Wei J., and Zivin J.A. Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator. Stroke 33 (2002) 1411-1415
23. Lapchak P.A., Araujo D.M., and Zivin J.A. Comparison of tenecteplase with alteplase on clinical rating scores following small clot embolic strokes in rabbits. Exp. Neurol. 185 (2004) 154-159
24. Lapchak P.A., Song D., Wei J., and Zivin J.A. Coadministration of NXY-059 and tenecteplase six hours following embolic strokes in rabbits improves clinical rating scores. Exp. Neurol. 188 (2004) 279-285
25. Lapchak P.A., Wei J., and Zivin J.A. Transcranial infrared laser therapy improves clinical rating scores after embolic strokes in rabbits. Stroke 35 (2004) 1985-1988
26. Lipton S.A. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults. NeuroRx 1 (2004) 101-110
27. Lipton S.A. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders. J. Alzheimer's Dis. 6 (2004) S61-S74
28. Muir K.W., and Lees K.R. Excitatory amino acid antagonists for acute stroke. Cochrane Database Syst. Rev. (2003) (CD001244)
29. Nowak L., Bregestovski P., Ascher P., Herbet A., and Prochiantz A. Magnesium gates glutamate-activated channels in mouse central neurones. Nature 307 (1984) 462-465
30. Parsons C.G., Gruner R., Rozental J., Millar J., and Lodge D. Patch clamp studies on the kinetics and selectivity of N-methyl-d-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology 32 (1993) 1337-1350
31. Parsons C.G., Panchenko V.A., Pinchenko V.O., Tsyndrenko A.Y., and Krishtal O.A. Comparative patch-clamp studies with freshly dissociated rat hippocampal and striatal neurons on the NMDA receptor antagonistic effects of amantadine and memantine. Eur. J. Neurosci. 8 (1996) 446-454
32. Parsons C.G., Danysz W., and Quack G. Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist-A review of preclinical data. Neuropharmacology 38 (1999) 735-767
33. Recommendations for standards regarding preclinical neuroprotective and restorative drug development (STAIR). Stroke 30 (1999) 2752-2758
34. Recommendations for clinical trial evaluation of acute stroke therapies (STAIR-II). Stroke 32 (2001) 1598-1606
35. Rikkert M.G., Dekkers W.J., Scheltens P., and Verhey F. Memantine in moderate-to-severe Alzheimer disease evidence and ethics based?. Alzheimer Dis. Assoc. Disord. 18 (2004) 47-48 (author reply 48)
36. Rogawski M.A., and Wenk G.L. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev. 9 (2003) 275-308
37. Rothman S.M., and Olney J.W. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann. Neurol. 19 (1986) 105-111
38. Rothman S.M., and Olney J.W. Excitotoxicity and the NMDA receptor-Still lethal after eight years. Trends Neurosci. 18 (1995) 57-58
39. Stieg P.E., Sathi S., Warach S., Le D.A., and Lipton S.A. Neuroprotection by the NMDA receptor-associated open-channel blocker memantine in a photothrombotic model of cerebral focal ischemia in neonatal rat. Eur. J. Pharmacol. 375 (1999) 115-120
40. Tariot P.N., Farlow M.R., Grossberg G.T., Graham S.M., McDonald S., and Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291 (2004) 317-324
41. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med. 333 (1995) 1581-1587
42. Zivin J.A., and Waud D.R. Quantal bioassay and stroke. Stroke 23 (1992) 767-773